Insider · CIK 0000938419
Walter Klemp V
Files at AMIX (Autonomix Medical, Inc.), MBRX (Moleculin Biotech, Inc.). First filing Jun 23, 2025, latest Jun 23, 2025.
In brief
Walter Klemp V files SEC Form 4 as CEO, president and director at MBRX (Moleculin Biotech, Inc.), and also at AMIX (Autonomix Medical, Inc.). Since Jun 23, 2025, Walter Klemp V has reported 1 open-market buy worth $250k and 0 open-market sells worth $0, the latest filed on Jun 23, 2025.
A track record needs three past buys with six months of prices behind them; Walter Klemp V has 0, so none is measured yet.
The newest scored trade: bought $250k of MBRX on Jun 23, 2025, filed Jun 23, 2025, scored 56 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MBRX: Moleculin Biotech, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Moleculin Biotech, Inc. | $250k 675,675 shares | +995% | - |
Transactions
Every row this insider has filed, 29 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | AMIX Autonomix Medical, Inc. | AGrant or award Common Stock | +13,000 | - | - | 20,118 | 35 d ago |
| Aug 3, 2026 | MBRX Moleculin Biotech, Inc. | POpen-market purchase Common Stock | +533,333 | - | - | 564,340 | Aug 5, 2026 |
| Aug 3, 2026 | MBRX Moleculin Biotech, Inc. | AGrant or award Series I Warrantsderivative | +1,599,999 | - | - | 1,926,335 | Aug 5, 2026 |
| Jun 20, 2026 | MBRX Moleculin Biotech, Inc. | MOption exercise Common Stock | +150 | - | - | 30,765 | Jun 24, 2026 |
| Jun 20, 2026 | MBRX Moleculin Biotech, Inc. | FTax withholding Common Stock | -37 | $2.88 | $107 | 30,728 | Jun 24, 2026 |
| Jun 22, 2026 | MBRX Moleculin Biotech, Inc. | MOption exercise Common Stock | +360 | - | - | 31,088 | Jun 24, 2026 |
| Jun 22, 2026 | MBRX Moleculin Biotech, Inc. | FTax withholding Common Stock | -88 | $3.12 | $275 | 31,007 | Jun 24, 2026 |
| Jun 20, 2026 | MBRX Moleculin Biotech, Inc. | MOption exercise Restricted Stock Unitsderivative | -150 | $0.00 | $0 | 326,696 | Jun 24, 2026 |
| Jun 22, 2026 | MBRX Moleculin Biotech, Inc. | MOption exercise Restricted Stock Unitsderivative | -360 | $0.00 | $0 | 326,336 | Jun 24, 2026 |
| Nov 12, 2025 | MBRX Moleculin Biotech, Inc. | AGrant or award Stock option (right to buy)derivative | +830,000 | - | - | 3,210,731 | Nov 14, 2025 |
| Nov 12, 2025 | MBRX Moleculin Biotech, Inc. | AGrant or award Performance Based Restricted Stock Unitsderivative | +750,000 | - | - | 3,960,731 | Nov 14, 2025 |
| Nov 4, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Common Stock | +28,750 | - | - | 772,357 | Nov 6, 2025 |
| Nov 4, 2025 | MBRX Moleculin Biotech, Inc. | FTax withholding Common Stock | -7,001 | $0.50 | $3,480 | 765,356 | Nov 6, 2025 |
| Nov 4, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Restricted Stock Unitsderivative | -28,750 | $0.00 | $0 | 2,380,731 | Nov 6, 2025 |
| Aug 11, 2025 | AMIX Autonomix Medical, Inc. | DDisposition to issuer Option (Right to buy)derivative | -8,773 | - | - | 1,250 | Aug 13, 2025 |
| Jun 20, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Common Stock | +3,750 | - | - | 62,046 | Jun 23, 2025 |
| Jun 20, 2025 | MBRX Moleculin Biotech, Inc. | FTax withholding Common Stock | -914 | $0.27 | $244 | 61,132 | Jun 23, 2025 |
| Jun 22, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Common Stock | +8,990 | - | - | 70,122 | Jun 23, 2025 |
| Jun 22, 2025 | MBRX Moleculin Biotech, Inc. | FTax withholding Common Stock | -2,190 | $0.27 | $585 | 67,932 | Jun 23, 2025 |
| Jun 23, 2025 | MBRX Moleculin Biotech, Inc. | POpen-market purchase Common Stock | +675,675 | $0.37 | $250k | 743,607 | Jun 23, 2025 |
| Jun 20, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 391,446 | Jun 23, 2025 |
| Jun 22, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Restricted Stock Unitsderivative | -8,990 | $0.00 | $0 | 382,456 | Jun 23, 2025 |
| Jun 23, 2025 | MBRX Moleculin Biotech, Inc. | POpen-market purchase Series E Warrantsderivative | -2,027,025 | - | - | 2,409,481 | Jun 23, 2025 |
| Jun 16, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Common Stock | +1,667 | - | - | 58,702 | Jun 18, 2025 |
| Jun 16, 2025 | MBRX Moleculin Biotech, Inc. | FTax withholding Common Stock | -406 | $0.69 | $278 | 58,296 | Jun 18, 2025 |
| Jun 16, 2025 | MBRX Moleculin Biotech, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,667 | $0.00 | $0 | 370,075 | Jun 18, 2025 |
| Nov 4, 2024 | MBRX Moleculin Biotech, Inc. | AGrant or award Stock option (right to buy)derivative | +100,000 | - | - | 213,152 | Nov 6, 2024 |
| Nov 4, 2024 | MBRX Moleculin Biotech, Inc. | AGrant or award Restricted Stock Unitsderivative | +115,000 | - | - | 328,152 | Nov 6, 2024 |
| Oct 25, 2024 | MBRX Moleculin Biotech, Inc. | AGrant or award Performance Based Restricted Stock Unitsderivative | +43,590 | - | - | 371,742 | Nov 6, 2024 |
Questions about Walter Klemp V
Answered from the filings on this page, as of the latest one.
Is Walter Klemp V buying or selling?
Not in the last 12 months. Walter Klemp V's latest open-market trade on SEC Form 4 was bought $250k of MBRX on Jun 23, 2025.
How did Walter Klemp V's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Walter Klemp V has 0.
Where does Walter Klemp V file Form 4?
Walter Klemp V has filed Form 4 at MBRX (Moleculin Biotech, Inc.) as CEO and President; AMIX (Autonomix Medical, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.